fasoracetam
Sign in to saveAlso known as NS 105
Fasoracetam () is an experimental drug of the racetam group which was never marketed. It is a putative nootropic that failed to show sufficient efficacy in clinical trials for vascular dementia. The drug was also subsequently repurposed for treatment of a variety of other conditions, such as attention deficit hyperactivity disorder (ADHD), but effectiveness for ADHD was disappointing and development of fasoracetam for most other conditions has been discontinued as well. In any case, it remains under development for treatment of DiGeorge syndrome. In addition to its clinical development, fasora
~4 min read
Encyclopedic overview
8 sectionsContents
- Pharmacology
- Chemistry
- History
- Society and culture
- Legality
- Australia
- Research
- References
Fasoracetam () is an experimental drug of the racetam group which was never marketed. It is a putative nootropic that failed to show sufficient efficacy in clinical trials for vascular dementia. The drug was also subsequently repurposed for treatment of a variety of other conditions, such as attention deficit hyperactivity disorder (ADHD), but effectiveness for ADHD was disappointing and development of fasoracetam for most other conditions has been discontinued as well. In any case, it remains under development for treatment of DiGeorge syndrome. In addition to its clinical development, fasoracetam is sold online and used non-medically as a nootropic.
==Pharmacology== Fasoracetam appears to modulate and stimulate all three groups of metabotropic glutamate receptors (mGluRs). It has been found to improve certain aspects of cognitive function in rodent studies. The drug is orally bioavailable and is excreted mostly unchanged in urine.
Excerpted from Wikipedia’s “fasoracetam” article, available under the CC BY-SA 4.0 licence.